Do analysts prefer TAOX or RFAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, TAOX or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than Synaptogenix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synaptogenix $300K 107.71 -$28.74M -$3.85 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Do analysts prefer TAOX or VANI?

Vivani Medical has a consensus price target of $3.75, suggesting a potential upside of 204.88%. Given Vivani Medical's stronger consensus rating and higher probable upside, analysts plainly believe Vivani Medical is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate TAOX or RFL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, TAOX or RFL?

Synaptogenix has higher earnings, but lower revenue than Rafael. Rafael is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synaptogenix $300K 107.71 -$28.74M -$3.85 N/A Rafael $980K 107.40 -$30.52M -$0.68 N/A

Is TAOX or RFL more profitable?

Synaptogenix has a net margin of -2,153.97% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix -2,153.97% -128.51% -97.54% Rafael -3,321.74% -41.27% -35.32%

Do analysts prefer TAOX or PLYX?

Polaryx Therapeutics has a consensus price target of $7.67, indicating a potential upside of 263.18%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Do analysts prefer TAOX or PYPD?

PolyPid has a consensus target price of $11.33, suggesting a potential upside of 111.64%. Given PolyPid's stronger consensus rating and higher possible upside, analysts plainly believe PolyPid is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PolyPid 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is TAOX or PYPD more profitable?

PolyPid has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix -2,153.97% -128.51% -97.54% PolyPid N/A -311.08% -150.83%

Synaptogenix (TAOX) Competitors

$4.32 0.00 (0.00%)

As of 10:51 AM Eastern

Compare

TAOX vs. RFAI, VANI, RFL, PLYX, and PYPD

Should you buy Synaptogenix stock or one of its competitors? Synaptogenix's main competitors and comparable companies include RF Acquisition Corp II (RFAI), Vivani Medical (VANI), Rafael (RFL), Polaryx Therapeutics (PLYX), and PolyPid (PYPD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Synaptogenix compare to RF Acquisition Corp II?

Synaptogenix (NASDAQ:TAOX) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

RF Acquisition Corp II has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. RF Acquisition Corp II's return on equity of 0.00% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
RF Acquisition Corp II	N/A	N/A	N/A

10.3% of Synaptogenix shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

RF Acquisition Corp II has lower revenue, but higher earnings than Synaptogenix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	107.71	-$28.74M	-$3.85	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, RF Acquisition Corp II had 1 more articles in the media than Synaptogenix. MarketBeat recorded 1 mentions for RF Acquisition Corp II and 0 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.00 equaled RF Acquisition Corp II'saverage media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
RF Acquisition Corp II	Neutral

Synaptogenix has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Summary

RF Acquisition Corp II beats Synaptogenix on 5 of the 8 factors compared between the two stocks.

How does Synaptogenix compare to Vivani Medical?

Synaptogenix (NASDAQ:TAOX) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Vivani Medical'saverage media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Vivani Medical	Neutral

Vivani Medical has a consensus price target of $3.75, suggesting a potential upside of 204.88%. Given Vivani Medical's stronger consensus rating and higher probable upside, analysts plainly believe Vivani Medical is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Vivani Medical has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Vivani Medical	N/A	-191.05%	-70.91%

Vivani Medical has lower revenue, but higher earnings than Synaptogenix. Vivani Medical is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	107.71	-$28.74M	-$3.85	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 53.3% of Vivani Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Synaptogenix has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.36, meaning that its stock price is 136% more volatile than the broader market.

Summary

Vivani Medical beats Synaptogenix on 9 of the 13 factors compared between the two stocks.

How does Synaptogenix compare to Rafael?

Synaptogenix (NASDAQ:TAOX) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Rafael'saverage media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Rafael	Neutral

Synaptogenix has higher earnings, but lower revenue than Rafael. Rafael is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	107.71	-$28.74M	-$3.85	N/A
Rafael	$980K	107.40	-$30.52M	-$0.68	N/A

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 32.9% of Rafael shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Synaptogenix has a net margin of -2,153.97% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Rafael	-3,321.74%	-41.27%	-35.32%

Synaptogenix has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Rafael has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Rafael beats Synaptogenix on 6 of the 11 factors compared between the two stocks.

How does Synaptogenix compare to Polaryx Therapeutics?

Synaptogenix (NASDAQ:TAOX) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Polaryx Therapeutics'average media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Polaryx Therapeutics	Neutral

Polaryx Therapeutics has a consensus price target of $7.67, indicating a potential upside of 263.18%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Polaryx Therapeutics has lower revenue, but higher earnings than Synaptogenix. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	107.71	-$28.74M	-$3.85	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

Polaryx Therapeutics has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Polaryx Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Polaryx Therapeutics	N/A	N/A	N/A

10.3% of Synaptogenix shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Polaryx Therapeutics beats Synaptogenix on 10 of the 13 factors compared between the two stocks.

How does Synaptogenix compare to PolyPid?

Synaptogenix (NASDAQ:TAOX) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, PolyPid had 2 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for PolyPid and 0 mentions for Synaptogenix. PolyPid's average media sentiment score of 0.61 beat Synaptogenix's score of 0.00 indicating that PolyPid is being referred to more favorably in the news media.

Company	Overall Sentiment
Synaptogenix	Neutral
PolyPid	Positive

PolyPid has a consensus target price of $11.33, suggesting a potential upside of 111.64%. Given PolyPid's stronger consensus rating and higher possible upside, analysts plainly believe PolyPid is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Synaptogenix has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, PolyPid has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Synaptogenix has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	107.71	-$28.74M	-$3.85	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A

PolyPid has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
PolyPid	N/A	-311.08%	-150.83%

Summary

PolyPid beats Synaptogenix on 9 of the 15 factors compared between the two stocks.

Get Synaptogenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAOX vs. The Competition

Export

Metric	Synaptogenix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32.32M	$12.62B	$7.28B	$13.01B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-1.12	797.33	274.92	25.63
Price / Sales	107.71	852.31	673.28	90.00
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	1.53	10.60	10.34	6.27
Net Income	-$28.74M	$2.84B	$3.49B	$360.12M
7 Day Performance	5.88%	-0.78%	-1.13%	-0.31%
1 Month Performance	10.49%	-1.63%	-3.55%	-3.67%
1 Year Performance	-27.52%	2.51%	14.81%	5.14%

Synaptogenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAOX Synaptogenix	0.0865 of 5 stars	$4.32 flat	N/A	-24.1%	$32.32M	$300K	N/A	4	Gap Down
RFAI RF Acquisition Corp II	0.928 of 5 stars	$32.30 +7.3%	N/A	+221.6%	$115.93M	N/A	N/A	N/A
VANI Vivani Medical	2.4838 of 5 stars	$1.26 -1.2%	$3.75 +198.8%	-18.0%	$113.20M	N/A	N/A	20	Positive News
RFL Rafael	0.1345 of 5 stars	$2.18 -4.5%	N/A	+38.8%	$112.84M	$920K	N/A	20	Gap Up
PLYX Polaryx Therapeutics	2.6064 of 5 stars	$2.04 +1.2%	$7.67 +276.7%	N/A	$101.45M	N/A	N/A	11

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TAOX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synaptogenix (TAOX) Competitors

TAOX vs. RFAI, VANI, RFL, PLYX, and PYPD

How does Synaptogenix compare to RF Acquisition Corp II?

Summary

How does Synaptogenix compare to Vivani Medical?

Summary

How does Synaptogenix compare to Rafael?

Summary

How does Synaptogenix compare to Polaryx Therapeutics?

Summary

How does Synaptogenix compare to PolyPid?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synaptogenix (TAOX) Competitors

TAOX vs. RFAI, VANI, RFL, PLYX, and PYPD

How does Synaptogenix compare to RF Acquisition Corp II?

Is TAOX or RFAI more profitable?

Do institutionals and insiders believe in TAOX or RFAI?

Which has better earnings and valuation, TAOX or RFAI?

Do analysts prefer TAOX or RFAI?

Does the media prefer TAOX or RFAI?

Which has more volatility and risk, TAOX or RFAI?

Summary

How does Synaptogenix compare to Vivani Medical?

Does the media prefer TAOX or VANI?

Do analysts prefer TAOX or VANI?

Is TAOX or VANI more profitable?

Which has better valuation and earnings, TAOX or VANI?

Do institutionals and insiders hold more shares of TAOX or VANI?

Which has more risk and volatility, TAOX or VANI?

Summary

How does Synaptogenix compare to Rafael?

Does the media prefer TAOX or RFL?

Which has higher earnings & valuation, TAOX or RFL?

Do institutionals & insiders hold more shares of TAOX or RFL?

Is TAOX or RFL more profitable?

Which has more risk & volatility, TAOX or RFL?

Do analysts rate TAOX or RFL?

Summary

How does Synaptogenix compare to Polaryx Therapeutics?

Does the media refer more to TAOX or PLYX?

Do analysts prefer TAOX or PLYX?

Which has higher valuation & earnings, TAOX or PLYX?

Is TAOX or PLYX more profitable?

Do insiders and institutionals believe in TAOX or PLYX?

Summary

How does Synaptogenix compare to PolyPid?

Do insiders and institutionals have more ownership in TAOX or PYPD?

Does the media prefer TAOX or PYPD?

Do analysts prefer TAOX or PYPD?

Which has more risk & volatility, TAOX or PYPD?

Which has preferable valuation & earnings, TAOX or PYPD?

Is TAOX or PYPD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools